Published by Josh White on 23rd May 2024
(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohort of the second arm in its phase one trial of AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, on Thursday.
URL: http://www.digitallook.com/dl/news/story/34314594/...